The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Cefmax     (6R,7S)-7-[[(2E)-2-(2-amino- 1,3-thiazol-4...

Synonyms: Bestcall, Tacef, CHEBI:55490, AC1NSF8K, DAP001178, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of cefmenoxime


High impact information on cefmenoxime


Chemical compound and disease context of cefmenoxime


Biological context of cefmenoxime


Anatomical context of cefmenoxime


Associations of cefmenoxime with other chemical compounds

  • In serum, the elimination half-life of ceftriaxone was twice as much as the elimination half-life of cefotiam or cefmenoxime (2.8 +/- 0.45 versus 1.4 +/- 0.25 or 1.3 +/- 0.4 h, respectively) [17].
  • The results of this study indicate that tubular secretion is the predominant mechanism of clearance for cefmenoxime and that probenecid alters the pharmacokinetics of the compound by competitively inhibiting its tubular secretion without affecting either the rate or the extent of its distribution [18].
  • When intact cells were treated with cefmenoxime, cephalothin, or cefoxitin, the MGICs correlated with the concentration of unlabeled beta-lactam required to reduce the subsequent binding of [35S]benzylpenicillin by 50% (ED50) for PBP 6 [19].
  • For patients with pathogen eradication, a significant difference between the two studies in time to eradication was found: 4.8 days for cefmenoxime-treated patients and 1.4 days for CIP- or TAZ-treated patients (P < 0.001) [20].
  • The in-vitro antibacterial activity of L-105 against clinical isolates of 18 bacterial species was compared with those of cefmenoxime, cefoperazone and cefazolin [21].

Gene context of cefmenoxime


Analytical, diagnostic and therapeutic context of cefmenoxime


  1. Role for dual individualization with cefmenoxime. Schentag, J.J., Smith, I.L., Swanson, D.J., DeAngelis, C., Fracasso, J.E., Vari, A., Vance, J.W. Am. J. Med. (1984) [Pubmed]
  2. Influence of cefmenoxime, ceftriaxone, latamoxef, and ceftazidime on the lysis of Klebsiella pneumoniae: a light and electron microscopic study. Ullmann, U., Hammer-Uschtrin, U. Am. J. Med. (1984) [Pubmed]
  3. Cefmenoxime efficacy, safety, and pharmacokinetics in critical care patients with nosocomial pneumonia. Schentag, J.J., Reitberg, D.P., Cumbo, T.J. Am. J. Med. (1984) [Pubmed]
  4. Cefmenoxime: in vitro activity. Stamm, J.M. Am. J. Med. (1984) [Pubmed]
  5. Cefmenoxime therapy in bacterial osteomyelitis. Sheftel, T.G., Cierny, G., Lefrock, J.L., Mader, J.T. Am. J. Med. (1984) [Pubmed]
  6. Concentrations of cefmenoxime in human tissues. Robens, W. Am. J. Med. (1984) [Pubmed]
  7. Comparative evaluation of cefmenoxime versus cefoxitin in serious infections. Bechard, D.L., Hawkins, S.H., Sutherland, S.C. Am. J. Med. (1984) [Pubmed]
  8. Cefmenoxime versus cefoxitin in the treatment of serious bacterial infections. Tan, J.S., File, T.M. Am. J. Med. (1984) [Pubmed]
  9. In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Watanabe, N., Katsu, K., Moriyama, M., Kitoh, K. Antimicrob. Agents Chemother. (1988) [Pubmed]
  10. Application of mathematical model to multiple-dose experimental chemotherapy for fatal murine pneumonia. Hishikawa, T., Kusunoki, T., Tsuchiya, K., Uzuka, Y., Sakamoto, T., Nagatake, T., Matsumoto, K. Antimicrob. Agents Chemother. (1991) [Pubmed]
  11. Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. Tsuchiya, K., Kondo, M., Kida, M., Nakao, M., Iwahi, T., Nishi, T., Noji, Y., Takeuchi, M., Nozaki, Y. Antimicrob. Agents Chemother. (1981) [Pubmed]
  12. Beta-lactamase stability and antibacterial activity of cefmenoxime (SCE-1365), a novel cephalosporin. Okonogi, K., Kuno, M., Kida, M., Mitsuhashi, S. Antimicrob. Agents Chemother. (1981) [Pubmed]
  13. Pharmacokinetic study of cefmenoxime (SCE 1365-CMX) in healthy adults. Fourtillan, J.B., Bryskier, A., Mignot, A., Borsa, F., Humbert, G. Am. J. Med. (1984) [Pubmed]
  14. Penetration of cefmenoxime into serum, gynecologic tissues, and heart valves. Daschner, F.D., Petersen, E.E., Frank, U., Hornig, D. Am. J. Med. (1984) [Pubmed]
  15. Clinical results and concentrations of cefmenoxime in serum, amniotic fluid, mother's milk, and umbilical cord. Weissenbacher, E.R., Adams, D., Gutschow, K., Peters-Welte, C., Luehr, H.G. Am. J. Med. (1984) [Pubmed]
  16. Cefmenoxime in surgical infections: treatment and penetration into peritoneal fluid and wound secretions. Wittke, R.R., Adam, D. Am. J. Med. (1984) [Pubmed]
  17. Comparative efficacy of cefotiam, cefmenoxime, and ceftriaxone in experimental endocarditis and correlation with pharmacokinetics and in vitro efficacy. Pangon, B., Joly, V., Vallois, J.M., Abel, L., Buré, A., Brion, N., Contrepois, A., Carbon, C. Antimicrob. Agents Chemother. (1987) [Pubmed]
  18. Effect of probenecid on the pharmacokinetics of cefmenoxime. Sennello, L.T., Quinn, D., Rollins, D.E., Tolman, K.G., Sonders, R.C. Antimicrob. Agents Chemother. (1983) [Pubmed]
  19. In vivo target of benzylpenicillin in Gaffkya homari. Wrezel, P.W., Ellis, L.F., Neuhaus, F.C. Antimicrob. Agents Chemother. (1986) [Pubmed]
  20. Modeling the response of pneumonia to antimicrobial therapy. Hyatt, J.M., Luzier, A.B., Forrest, A., Ballow, C.H., Schentag, J.J. Antimicrob. Agents Chemother. (1997) [Pubmed]
  21. In-vitro antibacterial activity of L-105, a new cephalosporin. Hikida, M., Inoue, M., Mitsuhashi, S. J. Antimicrob. Chemother. (1986) [Pubmed]
  22. In vitro activity and beta-lactamase stability of cefmenoxime. Neu, H.C., Labthavikul, P. Antimicrob. Agents Chemother. (1982) [Pubmed]
  23. Synergistic effects of romurtide and cefmenoxime against experimental Klebsiella pneumonia in mice. Tatara, O., Nakahama, C., Niki, Y. Antimicrob. Agents Chemother. (1992) [Pubmed]
  24. Levels of cefmenoxime in sera and peritoneal tissues of patients undergoing gastrointestinal surgery. Doi, R., Inoue, K., Hara, K., Tobe, T. Antimicrob. Agents Chemother. (1992) [Pubmed]
  25. Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis. Konishi, K. Antimicrob. Agents Chemother. (1986) [Pubmed]
WikiGenes - Universities